

SAIC-Frederick, Inc.Company Background

- Wholly owned subsidiary of Science Applications International Corporation (SAIC), a Fortune 500 company
- Located in Frederick, MD;
 1,750 employees
- Operates as the Prime Technical and Operations Contractor to the National Cancer Institute at Frederick (NCI-Frederick)
- FY2007–2008 Budget:
 \$380 million
- Mission: Develops and applies advanced technologies to accelerate the delivery of new treatments to patients with cancer and AIDS

Frederick



SAIC-Frederick Is the Operations and Technical Support Contractor for NCI-Frederick:

A Unique National Resource

- The only Federally Funded Research and Development Center (FFRDC) in the country focused exclusively on biomedical research and development (R&D)
 —to further the mission of the National Cancer Institute
- Nearly 3,000 government and contractor professionals and support staff conducting basic, translational, and preclinical research and development

Access to World-Class Technologies and Scientific Expertise

- Genetics and genomics
- Molecular screening and molecular diagnostic technologies
- Protein chemistry
- Protein expression
- Proteomics
- Cell and tissue image analysis
- Nanotechnology characterization
- Laboratory animal science
- Biopharmaceutical development, manufacturing, and regulatory support
- Mouse models of human cancer
- Advanced biomedical computing
- Viral technologies





Advanced Technology Partnerships Initiative (ATPI)

NCI-Frederick works to accelerate progress against cancer and AIDS through the ATPI

- Initiated in 2007 to accelerate the delivery of new discoveries, technologies, diagnostics, and therapeutics to cancer patients, as part of a National Cancer Institute strategic imperative
- NCI-Frederick leverages advanced technologies and resources, and public-private partnerships
- Includes business mechanisms and contractual agreements such as:
 - Material Transfer Agreements (MTA)
 - β -Testing Agreements (platform technology development)
 - Cooperative Research & Development Agreements (CRADA)
 - Clinical Trial CRADAs (CT-CRADA)
 - Clinical Trial Agreements (CTA)
 - Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) support
 - Guest Researcher Agreements



The Future of R&D at NCI-Frederick: Advanced Technology Research Facility

The ATPI includes enhancement of capabilities, programs, and operational efficiencies of NCI-Frederick, through the Advanced Technology Research Facility, planned for development and commissioning in the Frederick vicinity by 2011

- 330,000 square feet of R&D laboratories, biopharmaceutical development and cGMP production, training, and collaboration space
- "Collaboratory" concept to facilitate cooperative R&D and partnership opportunities and projects through the ATPI
- Research campus setting with opportunities for collocation of synergistic biomedical research institutions and life-science companies

